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INTRODUCTION
Neuroblastoma and Wilms tumor are the two most common
extracranial solid tumors in children younger than age 15 years,
accounting for approximately 13.6% of malignancies in the
pediatric population [1]. Similarities between these tumors include
their embryonal origin, a peak incidence in children younger than
5 years of age, and a predominantly abdominal presentation (65%of
neuroblastomas and all Wilms tumors) [2]. However, Wilms tumor
is associated with a high rate of cure [3], while children with high-
risk neuroblastoma fare poorly despite intensive therapy [4]. In
Wilms tumor, the evolution of therapy has focused on achieving
higher cure rates with a minimization of long-term adverse effects.
Although there has been a similar focus in children with low or
intermediate risk neuroblastoma, treatment of patients with high-
risk disease has become increasingly intensified [5]. In prior
treatment eras, children with Wilms tumor and low or intermediate
risk neuroblastoma were exposed to more aggressive multimodal
therapies, including radical surgery, orthovoltage radiation, and
chemotherapy. Consequently, long-term survivors of low or
intermediate risk neuroblastoma as well as Wilms tumor may
experience significant long-term adverse effects.
Although several publications have described the long-term
medical complications from Wilms tumor [6–11] and neuro-
blastoma [12–19], there are few studies describing the health-
related quality of life (HRQL) of these survivors. Barr and
colleagues compared HRQL between survivors of Wilms tumor
(stages 2–5) and advanced neuroblastoma (stage 4 and inoperable
stage 3) using the Health Utilities Index (HUI) in a cohort of
78 patients, 5 years after completion of their therapy [20]. There
was no difference in mean overall HRQL utility scores between
the two populations, although survivors of Wilms tumor were more
likely to be assessed by their parents as having no disabilities.
Survivors of neuroblastoma had a higher frequency of deficits in
hearing and speech, which is consistent with the high doses of
cisplatin that are typically included in treatment regimens for high-
risk disease [21,22]. In another study of 19 patients receiving
therapy for high-risk neuroblastoma, decrements in HRQL were
noted during the period immediately following diagnosis and in the
first few weeks after bone marrow transplantation [23]; however,
this study did not assess long-termoutcomes. Thegreatestmorbidity
was observed in the pain, self-care, mobility, and emotion domains.
The goal of the present study was to assess HRQL in long-term
survivors of Wilms tumor and neuroblastoma, and to examine the
sociodemographic, disease and treatment variables that influence
these outcomes. We examined data from the Childhood Cancer
Survivor Study (CCSS), a follow-up study of approximately 14,000
Background. Long-term survivors of Wilms tumor and neuro-
blastoma may experience significant late adverse effects from their
disease and its therapy. Little is known, however, about the health-
related quality of life experienced by these survivors. Procedure.
Health-related quality of life, measured by the 36-Item Short Form
Health Survey (SF-36), was assessed from self-report in adult
survivors of Wilms tumor (N¼654) and neuroblastoma (N¼432)
who participated in the Childhood Cancer Survivor Study. Results.
More than 90% of the study population was 18–34 years old at
interview, and 58% were females. There was no significant
difference on any SF-36 subscale or summary scale between the
two diagnostic groups. On average, survivors reported no decrement
on the Physical Component Summary scale of the SF-36 when
compared to population norms. However, both groups scored
significantly below the population mean score (50) on the Mental
Component Summary Scale of the SF-36 (Wilms tumor
mean¼41.66, standard error¼2.19, P<0.0001; neuroblastoma
mean¼42.41, standard error¼ 2.23, P< 0.0001) reflecting
decreased emotional health. Independent risk factors for lower
scores on this scale included female gender, Native American race,
unemployment, and household income below $20,000. Conclu-
sions. Adult survivors of childhood Wilms tumor and neuroblastoma
do not differ from population norms on most health-related quality of
life (HRQL) measures. These data, however, indicate that the
emotional well being of adult survivors may be compromised.
Health care providers should be aware of the risk of adverse out-
comes in emotional health evenmany years after treatment and cure.
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long-term survivors of pediatric cancer [24]. This cohort includes a
considerably larger group of survivors of Wilms tumor and
neuroblastoma and a longer period of follow-up than the above-
mentioned studies. Our primary a priori hypothesis was that the
prevalence of adverse outcomes in HRQL would be higher in
survivors of neuroblastoma than in survivors of Wilms tumor.
PATIENTS AND METHODS
Childhood Cancer Survivor Study (CCSS)
The survivors of Wilms tumor and neuroblastoma evaluated in
this study are a subset of the 14,370 participants in the CCSS. The
methodology of theCCSS and a description of the study participants
have been published in detail previously [24]. Briefly, the CCSS is a
multi-institutional study aimed at determining the late adverse
outcomes following treatment for cancer during childhood or
adolescence. The CCSS cohort consists of survivors of childhood
cancer whowere diagnosed before the age of 21 years between 1970
and 1986, and who were alive at least 5 years from their original
diagnosis. At the time of study enrollment (1995–1996 for most
participants), a comprehensive baseline questionnaire was com-
pleted by the participant (if aged 18 years or older) or his or her
parent (if younger than age 18 years), and detailed medical
information was abstracted from hospital records. Several sub-
sequent questionnaires have been completed by the study
participants, including a questionnaire on quality of life that is the
basis for this analysis. The study methodology was approved by the
Institutional Review Board of each of the 26 participating insti-
tutions and informed consent was obtained from each participant or
his or her parent or guardian.
Survivors of Wilms Tumor or Neuroblastoma
Eligibility for this analysis of CCSS participants was limited to
those diagnosedwithWilms tumor or neuroblastomawhowere aged
18 years or older at the time of the CCSS follow-up questionnaire
that was administered in 2002 and 2003. Information regarding
HRQL and current sociodemographic status (age at interview,
household income, health insurance, education, marital status,
employment status) were obtained as part of this follow-up ques-
tionnaire. Baseline demographics (gender, race), disease variables
(diagnosis, age at diagnosis, location of tumor in neuroblastoma
patients), and treatment variables (chemotherapy including alkylat-
ing agent score and anthracycline score, surgery including history of
laminectomy, laparotomy, nephrectomy or thoracotomy, and
radiation field and dose) were abstracted from the CCSS database.
These data were also used to determine if participants had a major
medical condition. This composite measure was defined as the
presence of one or more of seizures, congestive heart failure,
myocardial infarction, stroke, cirrhosis, pulmonary disease requir-
ing oxygen, solid organ transplant, second malignancy, amputation,
or joint replacement [25].
Measures of Health-Related Quality of Life
HRQLwas assessed with the 36-Item Short FormHealth Survey
(SF-36). The SF-36 is a widely used and well-validated global
HRQL instrument that contains eight individual subscales repre-
senting physical, emotional, and social well being [26]. These
subscales are physical function, role function—physical (assessing
role limitations caused by physical factors), bodily pain, social
function, mental health, role function—emotional (assessing role
limitations caused by emotional factors), vitality, and general
health. The SF-36 can also be scored as two summary scales, the
Physical Component Summary scale (PCS) and theMental Compo-
nent Summary scale (MCS).General population norms are available
for the subscales and summary scales [27]. Data are normalized and
presented as t-scores with a normal population mean score set at
50 with a standard deviation of 10.
Statistical Analysis
Descriptive statistics for the sociodemographic, disease and
treatment variables were calculated separately for the Wilms tumor
and neuroblastoma survivor groups. Means and standard deviations
were calculated for the eight subscales and two summary scales of
the SF-36, stratified by diagnosis, sociodemographic variables, and
the presence or absence of a major medical condition. Means were
compared between the two diagnostic groups and between levels of
the sociodemographic variables with two sample t-tests. General
linear regression was used to evaluate the association between
diagnosis, sociodemographic variables, major medical condition,
and each of the HRQL outcomes in adjusted models [28]. Results
are reported as means and standard deviations with two-sided
P-values.
To determine the diagnostic and treatment characteristics of
the survivors who indicated poor HRQL, we dichotomized those
patients with complete treatment data into two groups for each
SF-36 subscale and summary scale. Individuals who scored lower
than 40 (greater than one standard deviation below themean) on any
of the SF-36 subscales or summary scales were considered to have
poor HRQL in that domain. Frequencies and percents of poor
outcomes on each of the SF-36 subscales and summary scales were
calculated separately forWilms tumor and neuroblastoma survivors
by diagnostic and treatment variables, and proportions were
compared with Chi-squared tests. Multiple variable unconditional
logistic regression was used to evaluate the magnitude of the
associations between diagnostic and treatment variables and poor
HRQL. Final models were selected using goodness of fit methods
and by comparing Chi-squared values between full and reduced
models [29]. Results are reported as adjusted odds ratios with 95%
confidence intervals. SAS version 9.1 (Cary, N.C.) was used for
all analyses.
RESULTS
Characteristics of the Study Cohort
A total of 1,440 patients (843Wilms tumor, 597 neuroblastoma)
were eligible for these analyses. Of these, 654 (77.6%)Wilms tumor
survivors and 432 (72.4%) neuroblastoma survivors completed the
HRQL follow-up questionnaire. The 1,086 study participants were
statistically similar to the 354 eligible non-participants in terms of
employment status and current health insurance, but differed
significantly for several other sociodemographic characteristics.
Non-participants tended to be somewhat younger than participants
(48.9% vs. 43.0% age 18–24 years), weremore likely to be of Black
race (10.7% vs. 3.5%), were less likely to have a college degree
(25.7% vs. 40.3%), were more likely to be in the lowest annual
Pediatr Blood Cancer DOI 10.1002/pbc
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household income category (14.1% vs. 9.7% with <$20,000), and
were more likely to have a major medical condition (12.7% vs.
8.9%). The sociodemographic characteristics of the study partic-
ipants are displayed in Table I. Survivors of neuroblastoma were
younger and more likely to describe themselves as ‘‘single’’ than
were survivors of Wilms tumor.
Treatment data were available for 1,019 of the 1,086 patients who
completed the HRQL follow-up questionnaire. Diagnosis and
treatment characteristics of these survivors are shown in Table II.
Survivors of Wilms tumor were more likely than survivors of
neuroblastoma to have received either chemotherapy or radiation, to
have received an anthracycline, or radiation to the abdomen or pelvis,
or to have undergone a nephrectomy. In contrast, survivors of
neuroblastoma were more likely than survivors of Wilms tumor to
have been followed for a longer period of time fromdiagnosis, to have
been treated with either surgery alone or surgery and radiation
(compared to treatment with combined modality therapy that includ-
ed chemotherapy), to have received an alkylating agent, or radiation
to the head, neck or spine, or to have undergone a laminectomy or
thoracotomy.
HRQL Outcomes
Adjusted mean scores on the PCS and MCS are displayed in
Table III by sociodemographic variables and diagnostic category.
There was no difference between the Wilms tumor and neuro-
blastoma survivors on either of the two summary scales. Overall,
survivorswhowere looking forwork or unable towork (compared to
those employed or not seeking paid work) and those without health
insurance (compared to those with health insurance) scored
significantly lower on the PCS (indicating decreased HRQL due
to poor physical function), while patients aged 18–24 years scored
significantly higher on the PCS than those older than age 35 years.
On the MCS, both the Wilms tumor (mean¼ 41.66, SE¼ 2.19)
Pediatr Blood Cancer DOI 10.1002/pbc
TABLE I. Characteristics of the Study Population
Wilms tumor Neuroblastoma Total
P-value*
N¼ 654 N¼ 432 N¼ 1,086
N % N % N %
Age group at the time of questionnaire 0.007
18–24 years 261 (39.9) 206 (47.7) 467 (43.0)
25–34 years 343 (52.4) 203 (47.0) 546 (50.3)
35þ years 50 (7.6) 23 (5.3) 73 (6.7)
Gender 0.94
Female 383 (58.6) 252 (58.3) 635 (58.5)
Male 271 (41.4) 180 (41.7) 451 (41.5)
Race/ethnicity 0.65
White 589 (90.1) 401 (92.8) 990 (91.2)
Native American 4 (0.6) 2 (0.5) 6 (0.6)
Asian 4 (0.6) 6 (1.4) 10 (0.9)
Black 30 (4.6) 8 (1.9) 38 (3.5)
Hispanic 25 (3.8) 11 (2.5) 36 (3.3)
Other 2 (0.3) 4 (0.9) 6 (0.6)
Household income (annual) 0.57
<$20,000 63 (9.6) 42 (9.7) 105 (9.7)
$20–59,000 270 (41.3) 185 (42.8) 455 (41.9)
$60–99,999 163 (24.9) 93 (21.5) 256 (23.6)
$1,00,000þ 82 (12.5) 44 (10.2) 126 (11.6)
Unknown 76 (11.6) 68 (15.7) 144 (13.3)
Education 0.88
<High school 26 (4.0) 19 (4.4) 45 (4.1)
High school graduate 362 (55.4) 235 (54.4) 597 (55.0)
College graduate 262 (40.1) 176 (40.7) 438 (40.3)
Unknown 4 (0.6) 2 (0.5) 6 (0.6)
Marital status <0.0001
Married or living as married 304 (46.5) 141 (32.6) 445 (41.0)
Single 323 (49.4) 275 (63.7) 598 (55.1)
Divorced or separated 20 (3.1) 13 (3.0) 33 (3.0)
Unknown 7 (1.1) 3 (0.7) 10 (0.9)
Employment 0.84
Employed or caring for home 445 (68.0) 287 (66.4) 732 (67.4)
Looking for work or unable to work 64 (9.8) 39 (9.0) 103 (9.5)
Student 145 (22.2) 106 (24.5) 251 (23.1)
Current health insurance 573 (87.6) 377 (87.3) 950 (87.5) 0.87
Major medical condition 54 (8.3) 43 (10.0) 97 (8.9) 0.34
*P-value reported for Chi-squared comparison of Wilms tumor versus neuroblastoma.
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and neuroblastoma (mean¼ 42.41, SE¼ 2.23) groups scored
almost one standard deviation below the population mean of 50
(P< 0.0001 for both comparisons). Females (compared to males),
Native Americans (compared to those who identified themselves as
white), and those with an annual household income less than
$20,000 (compared to a household income greater than $100,000)
scored significantly lower on the MCS.
Table IV demonstrates the adjusted mean SF-36 subscale scores
by diagnostic group and sociodemographic variables. Aswith the two
summary scales, there were no differences between theWilms tumor
and neuroblastoma survivors on any of the eight subscales. Females
scored significantly lower thanmales on all of the subscales except for
bodily pain. Physical function scores were lower in those survivors
who had not graduated from college, were looking for work or unable
Pediatr Blood Cancer DOI 10.1002/pbc
TABLE II. Diagnosis and Treatment Characteristics*
Wilms tumor Neuroblastoma Total
P-value**
N¼ 612 N¼ 407 N¼ 1,019
N % N % N %
Age at diagnosis (Wilms tumor)
<2 years 193 (31.5)
2–5 years 334 (54.6)
6þ years 85 (13.9)
Age at diagnosis (neuroblastoma)
 1 year 219 (53.8)
1þ years 188 (46.2)
Survival time 0.006
16–20 years 243 (39.7) 122 (30.0) 365 (35.8)
21–25 years 193 (31.5) 149 (36.6) 342 (33.6)
26–30 years 135 (22.1) 96 (23.6) 231 (22.7)
31–35 years 41 (6.7) 40 (9.8) 81 (7.9)
Treatment modalitiesa
Chemotherapy 601 (98.2) 237 (58.2) 838 (82.2) <0.0001
Radiation 393 (64.2) 203 (49.9) 596 (58.5) 0.0001
Surgery 612 (100.0) 400 (98.3) 1,012 (99.3) 0.001
Treatment regimen
Surgery alone 9 (1.5) 103 (25.3) 112 (11.0) <0.0001
Chemotherapy þ/ surgery 210 (34.3) 102 (25.1) 312 (30.6) 0.002
Radiation þ/ surgery 3 (0.5) 67 (16.5) 70 (6.9) <0.0001
Chemotherapy and radiation þ/
surgery
390 (63.7) 135 (33.2) 525 (51.5) <0.0001
Anthracyclines received <0.0001
Yes 224 (36.6) 93 (22.9) 317 (31.1)
No 388 (63.4) 314 (77.1) 702 (68.9)
Alkylating agents received <0.0001
Yes 46 (7.5) 193 (47.4) 239 (23.5)
No 566 (92.5) 214 (52.6) 780 (76.5)
Radiation therapy site
Head or cranial 0 (0.0) 41 (10.1) 41 (10.1) <0.0001
Neck 4 (0.7) 30 (7.4) 34 (3.3) <0.0001
Chest 134 (21.9) 79 (19.4) 213 (20.9) 0.15
Abdomen 373 (60.9) 113 (27.8) 486 (47.7) <0.0001
Spine 0 (0.0) 13 (3.2) 13 (1.3) <0.0001
Pelvis 188 (30.7) 64 (15.7) 252 (24.7) <0.001
Limb 0 (0.0) 7 (1.7) 7 (0.7) 0.36
Total body 0 (0.0) 7 (1.7) 7 (0.7) 0.36
Surgical procedures
Laminectomy 0 (0.0) 22 (5.4) 22 (2.2) <0.0001
Laparotomy 170 (27.8) 126 (31.0) 296 (29.0) 0.15
Nephrectomy 576 (94.1) 23 (5.7) 599 (58.8) <0.0001
Thoracotomy 16 (2.6) 55 (13.5) 71 (7.0) <0.0001
Treatment era 0.91
1970–1979 262 (42.8) 210 (51.6) 472 (46.3)
1980–1986 350 (57.2) 197 (48.4) 547 (53.7)
*Limited to those with complete treatment data; **P-value reported for Chi-squared or Fisher exact test comparison of Wilms tumor versus
neuroblastoma; aPatients may have been treated with more than one modality.
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to work, had an annual household income less than $20,000, did not
have health insurance, or reported a major medical condition.
The results of the multiple variable models evaluating the
association between diagnostic and treatment variables and poor
outcome (score< 40) on the summary scales or subscales of the SF-
36 are shown in Tables V and VI, stratified for the two diagnostic
categories. In survivors of Wilms tumor (Table V), the final model
included gender, age group at questionnaire, chest radiation,
abdominal radiation, and pelvic radiation. After adjusting for the
other variables in themodel, no variablewas associated significantly
with a poor PCS score. However, females were more likely to have
a poor MCS score than males (OR¼ 1.67, 95% CI¼ 1.1–2.5,
P< 0.05). Female gender was also associated with a significantly
increased risk of a poor outcome on the general health (OR¼ 2.13,
95% CI¼ 1.3–3.4, P< 0.05), vitality (OR¼ 1.89, 95% CI¼ 1.3–
2.7, P< 0.05), and role function—emotional (OR¼ 1.90, 95%
CI¼ 1.3–2.8, P< 0.05) subscales. Pelvic radiation was associated
with poor outcome on the role function—physical subscale
(OR¼ 1.80, 95% CI¼ 1.0–3.3, P< 0.05).
In survivors of neuroblastoma (Table VI), the final model
included gender, age at questionnaire, survival time, abdominal
radiation, spinal radiation, pelvic radiation, and laminectomy. As
with Wilms tumor, no variable was associated with a poor PCS
score. Again, females were more likely to have a poor MCS score
than males (OR¼ 1.66, 95% CI¼ 1.0–2.8, P< 0.05). Female
gender was also associated with a significantly increased risk of a
poor outcome on the role function—physical (OR¼ 2.07, 95%
CI¼ 1.1–4.0,P< 0.05), general health (OR¼ 2.10, 95%CI¼ 1.2–
Pediatr Blood Cancer DOI 10.1002/pbc
TABLE III. Adjusted Mean Scores on SF-36 Summary Scales
PCS MCS
Meanb SE P-value Meanb SE P-value
Diagnosis
Wilmsa 54.17 1.43 41.66 2.19
Neuroblastoma 53.42 1.45 0.15 42.41 2.23 0.36
Age group
18–24 years 55.92 1.44 <0.001 41.74 2.21 0.36
25–34 years 53.62 1.42 0.09 40.99 2.18 0.14
35þ yearsa 51.83 1.70 43.37 2.60
Gender
Malea 54.31 1.43 43.79 2.20
Female 53.28 1.45 0.05 40.28 2.22 <0.001
Race/ethnicity
Whitea 51.53 1.18 46.24 1.81
Native American 55.01 3.60 0.31 31.34 5.52 <0.001
Asian 55.00 2.89 0.19 37.66 4.43 0.03
Black 52.08 1.74 0.69 48.91 2.67 0.21
Hispanic 51.48 1.76 0.97 48.69 2.70 0.26
Other 57.66 3.45 0.08 39.38 5.29 0.20
Household income (annual)
<$20,000 52.13 1.57 0.02 38.02 2.41 <0.001
$20–59,999 53.21 1.44 0.05 43.14 2.20 0.84
$60–99,000 55.16 1.51 0.77 43.76 2.31 0.80
$100,000þa 54.89 1.60 43.40 2.45
Education
<High school 51.95 1.84 0.05 40.15 2.81 0.09
High school graduate 54.69 1.45 <0.001 43.79 2.22 0.07
College graduatea 52.93 1.38 42.20 2.11
Marital status
Married or living as marrieda 52.43 1.49 43.23 2.28
Single 51.93 1.52 0.42 43.72 2.32 0.61
Divorced or separated 54.14 2.05 0.15 39.01 3.15 0.04
Employment
Employed or caring for homea 56.10 1.47 42.92 2.25
Looking for work or unable to work 48.95 1.52 <0.001 40.50 2.32 0.09
Student 56.33 1.55 0.74 42.69 2.37 0.83
Health insurance
Yesa 54.87 1.54 42.01 2.35
No 52.72 1.41 0.01 42.06 2.16 0.97
Major medical condition
Noa 54.53 1.39 42.93 2.13
Yes 53.06 1.58 0.11 41.14 2.42 0.20
PCS, physical component summary scale;MCS,mental component summary scale; SE, standard error; aReference category; bAdjusted for all of the
other variables in the model.
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712 Nathan et al.
3.8, P< 0.05), vitality (OR¼ 2.12, 95% CI¼ 1.4–3.2, P< 0.05),
and role function—emotional (OR¼ 1.56, 95% CI¼ 1.0–2.5,
P< 0.05) subscales. Patients who received pelvic radiation
demonstrated an increased risk of poor outcome on the general
health subscale (OR¼ 2.32, 95% CI¼ 1.0–5.4, P< 0.05). Patients
who underwent a laminectomy had an increased risk of a poor
outcome on the physical function (OR¼ 5.48, 95% CI¼ 1.9–16.0,
P< 0.05) and bodily pain (OR¼ 4.38, 95% CI¼ 1.6–12.0,
P< 0.05) subscales.
DISCUSSION
This follow-up study adds to the literature on health outcomes
among long-term survivors of Wilms tumor and neuroblastoma by
evaluating HRQL. In this population of young adults who were
treated for cancer at a very young age, we found no evidence for
significant deficits in HRQL measures representing physical well
being or functioning. However, there is a clear pattern of poor
emotional health evident in both diagnostic groups. Survivors
scored considerably below population norms on the MCS scale of
the SF-36, a composite measure reflecting performance on the
vitality, social function, role-emotional, and mental health sub-
scales. This is of particular concern because scores below 42 on this
summary scale have been shown to have high sensitivity and
specificity for diagnoses of depression in other studies [30].
Although women consistently scored lower than men on these
measures, the pattern of lower scores was evident for both sexes.
Poorer HRQL outcomes amongst females have been reported in
many studies of both acute and chronic illness [31–33], and female
survivors of childhood cancer have been demonstrated previously to
have a higher likelihood of adverse health status [25] and poorer
HRQL than males [34]. In addition to female gender, several other
sociodemographic factors correlated with overall worse outcome on
one or more measures of HRQL. These included patients who were
unemployed or looking for work, those with lower annual incomes,
and those who had not graduated from college. Importantly, no
specific disease characteristics or treatment exposures were pre-
dictive of poorer performance on the MCS subscale for either
diagnosis. Thus, treatment intensity is not predictive of poorer
emotional health and all survivors should be evaluated for this
adverse outcome regardless of the severity of their initial cancer.
These findings may be important to primary care physicians, who
are themost likely health care providers to have regular contact with
this population and may be most able to screen for depression or
anxiety during routine care visits.
We observed no difference on any measure of HRQL between
diagnostic groups. This might be attributable to two factors. First,
the survival of patients with high-risk neuroblastoma is poor [35],
resulting in a relative absence of survivors of high-stage disease.
Most survivors of high-risk neuroblastoma experience one or more
long-term complications of their disease or therapy, with almost
one third reporting severe or life-threatening complications [19].
The most common of these are hearing loss, hypothyroidism and
acute ovarian failure. Although stage information was not captured
in the CCSS database, over 40% of the neuroblastoma survivors in
the current cohort did not receive any chemotherapy, suggesting a
high proportion of patients with lower stage disease who are less
likely to develop long-term adverse effects. Alternatively, the
absence of a difference in HRQL between the two groups in this
study may be explained by the historical use of more aggressive
multi-modal therapies in many patients withWilms tumor treated in
prior eras. This might serve to increase their risk of long-term
morbidity compared to contemporary cohorts. Almost two-thirds of
Wilms tumor survivors in this cohort received radiotherapy and over
one-third received anthracycline chemotherapy. These treatment
modalities may increase the risk of the long-term sequelae ofWilms
tumor therapy, including chronic renal failure [36], congestive heart
failure [37], and second malignant neoplasms [7], all of which
would have impact on HRQL.
As expected, both radiation and surgery for local control of the
primary tumor impacted on HRQL. Survivors of Wilms tumor who
had received pelvic radiation were more likely to perform poorly on
the role function—physical subscale of the SF-36. Pelvic radiation
in patients with Wilms tumor has been linked to premature ovarian
failure, infertility, adverse pregnancy outcomes [38], and second
malignant neoplasms [7]. Survivors of Wilms tumor who had
received chest radiation were more likely to perform poorly on the
social function and role function—emotional subscales of the
SF-36. The use of chest radiation inWilms tumor is usually reserved
for patients with metastatic disease and this may reflect a group of
survivors of higher risk disease. In survivors of neuroblastoma, a
history of laminectomy was associated with an increased risk of
poor performance on the role function—physical and bodily pain
subscales of the SF-36. This might reflect the long-term con-
sequences of this surgery which include scoliosis [19,39]. However,
children requiring laminectomy are more likely to have presented
with spinal cord compression and thus, their poor performance
might reflect residual neurologic compromise [40]. In addition,
pelvic radiation was linked to poor general health in this group
of patients.
This study has some methodological limitations that should be
considered when interpreting the results. First, although the SF-36
has beenvalidated as a self-report instrument, data regarding current
socioeconomic status and medical complications were generated
similarly from self report, and were not validated externally.
Second, incomplete participation in the CCSS by eligible patients
may have biased our results if survivorswith poorerHRQLwere less
(or more) likely to join the CCSS cohort and to continue to
contribute information to the study. Although the response rate for
theHRQLquestionnairewas good amongst those survivors enrolled
in the CCSS (75.4%), non-respondents tended to be of lower
socioeconomic status than participants and were somewhat more
likely to have reported a major medical condition. These differ-
ences, not uncommon in health outcome studies, suggest caution be
exercised when generalizing our findings to low social and
economic strata. Third, the CCSS did not collect disease stage
information because of a lack of consistency between staging
systems used at different institutions. As a result, we cannot cate-
gorize survivors by disease stage, nor can we show the relationship
between stage and HRQL outcomes. Finally, all members of this
cohortwere treated in the period between 1970 and 1986 and readers
must be cautious in generalizing these results to patients treated on
more contemporary protocols. Changes in the intensity of therapy,
particularly in patients with Wilms tumor and those with low or
intermediate risk neuroblastoma may result in different HRQL
outcomes. Contemporary protocols often use lower doses of
radiation and there have been improvements in the techniques and
equipment used to deliver radiotherapy. There have been concom-
itant improvements in surgical techniques. Thus, patients treated on
more recent protocols warrant separate investigation.
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Despite differences in therapy, long-term survivors of Wilms
tumor and neuroblastoma do not differ in their assessment ofHRQL.
Their physical well being and functioning is comparable to
population norms, but they score significantly below these norms
on measures of emotional health. Women and survivors in lower
sociodemographic strata demonstrate the greatest risk of adverse
outcomes. Health care providers must be sensitive to the risk for
adverse outcomes in these vulnerable groups and institute
appropriate screening and intervention.
ACKNOWLEDGMENT
CCSS is supported by a grant from the National Cancer Institute
(U24 CA55727) and by funds provided to the University of
Minnesota Cancer Center by the Children’s Cancer Research Fund.
L.Z. is funded, in part, by a grant from the Lance Armstrong
Foundation (G 00-12-076-02). M.G. holds the POGO Chair in
Childhood Cancer Control at the University of Toronto.
REFERENCES
1. Cancer Incidence and Survival among Children and Adolescents:
United States SEER Program 1975–1995. In: Ries LAG, Smith
MA, Gurney JG, et al., editors. Bethesda, MD: National Cancer
Institute; SEER Program; 1999.
2. Pizzo PA, Poplack DG. Principles and Practice of Pediatric
Oncology. Philadelphia, PA: LippincottWilliams&Wilkins; 2002.
3. Green DM, D’Angio GJ, Beckwith JB, et al. Wilms tumor. CA
Cancer J Clin 1996;46:46–63.
4. MatthayKK,Villablanca J, SeegerRC, et al. Treatment of high-risk
neuroblastoma with intensive chemotherapy, radiotherapy, auto-
logous bone marrow transplantation, and 13-cis-retinoic acid. N
Engl J Med 1999;341:1165–1173.
5. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the
diagnosis and treatment of neuroblastoma. Oncologist 2003;8:
278–292.
6. Sorensen K, Levitt G, Sebag-Montefiore D, et al. Cardiac
function in Wilms tumor survivors. J Clin Oncol 1995;13:1546–
1556.
7. Breslow NE, Takashima JR, Whitton JA, et al. Second malignant
neoplasms following treatment forWilm’s tumor:A report from the
National Wilms Tumor Study Group. J Clin Oncol 1995;13:1851–
1859.
8. Green DM, Donckerwolcke R, Evans AE, et al. Late effects of
treatment for Wilms tumor. Hematol Oncol Clin North Am
1995;9:1317–1327.
9. Egeler RM, Wolff JE, Anderson RA, et al. Long-term complica-
tions and post-treatment follow-up of patients with Wilms tumor.
Semin Urol Oncol 1999;17:55–61.
10. Paulino AC, Wen BC, Brown CK, et al. Late effects in children
treated with radiation therapy for Wilms tumor. Int J Radiat Oncol
Biol Phys 2000;46:1239–1246.
11. Hogeboom CJ, Grosser SC, Guthrie KA, et al. Stature loss
following treatment for Wilms tumor. Med Pediatr Oncol 2001;
36:295–304.
12. Willi SM,CookeK,Goldwein J, et al. Growth in children after bone
marrow transplantation for advanced neuroblastoma compared
with growth after transplantation for leukemia or aplastic anemia.
J Pediatr 1992;120:726–732.
13. Hovi L, Saarinen-Pihkala UM, Vettenranta K, et al. Growth in
children with poor-risk neuroblastoma after regimens with or
without total body irradiation in preparation for autologous bone
marrow transplantation. Bone Marrow Transplant 1999;24:1131–
1136.
14. Olshan JS, Willi SM, Gruccio D, et al. Growth hormone function
and treatment following bone marrow transplant for neuroblas-
toma. Bone Marrow Transplant 1993;12:381–385.
15. Holtta P, Alaluusua S, Saarinen-Pihkala UM, et al. Long-term
adverse effects on dentition in children with poor-risk neuroblas-
toma treated with high-dose chemotherapy and autologous stem
cell transplantation with or without total body irradiation. Bone
Marrow Transplant 2002;29:121–127.
16. Koyle MA, Hatch DA, Furness PD, 3rd, et al. Long-term
urological complications in survivors younger than 15 months of
advanced stage abdominal neuroblastoma. J Urol 2001;166:1455–
1458.
17. van Santen HM, de Kraker J, van Eck BL, et al. High incidence of
thyroid dysfunction despite prophylaxis with potassium iodide
during (131)I-meta-iodobenzylguanidine treatment in children
with neuroblastoma. Cancer 2002;94:2081–2089.
18. Weiss B, Vora A, Huberty J, et al. Secondary myelodysplastic
syndrome and leukemia following 131I-metaiodobenzylguanidine
therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol
2003;25:543–547.
19. Laverdiere C, Cheung NK, Kushner BH, et al. Long-term
complications in survivors of advanced stage neuroblastoma.
Pediatr Blood Cancer 2005;45:324–332.
20. Barr RD, Chalmers D, De Pauw S, et al. Health-related quality of
life in survivors of Wilms tumor and advanced neuroblastoma: A
cross-sectional study. J Clin Oncol 2000;18:3280–3287.
21. Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-
related ototoxicity in children: Long-term follow-up reveals
continuous worsening of hearing loss. J Pediatr Hematol Oncol
2004;26:649–655.
22. Simon T, Hero B, Dupuis W, et al. The incidence of hearing
impairment after successful treatment of neuroblastoma. Klin
Padiatr 2002;214:149–152.
23. Nathan PC, Furlong W, De Pauw S, et al. Health status of young
children during therapy for advanced neuroblastoma. Pediatr
Blood Cancer 2004;43:659–667.
24. Robison LL, Mertens AC, Boice JD, et al. Study design and cohort
characteristics of the Childhood Cancer Survivor Study: A multi-
institutional collaborative project. Med Pediatr Oncol 2002;38:
229–239.
25. Hudson MM, Mertens AC, Yasui Y, et al. Health status of
adult long-term survivors of childhood cancer: A report from
the Childhood Cancer Survivor Study. Jama 2003;290:1583–
1592.
26. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health
survey (SF-36). I. Conceptual framework and item selection. Med
Care 1992;30:473–483.
27. McHorney CA, Kosinski M, Ware JE, Jr. Comparisons of the costs
and quality of norms for the SF-36 health survey collected by mail
versus telephone interview: Results from a national survey. Med
Care 1994;32:551–567.
28. Khattree R, Naik DN. Multivariate data reduction and discrimina-
tion with SAS software. Cary, NC: SAS Institute; 2000.
29. Kleinbaum DG, Klein M. Logistic regression: A self learning text.
New York, NY: Springer-Verlag; 2002.
30. Ware JE, Gandek B, Group IP. The SF-36 Health Survey:
Development and use in mental health research and the IQOLA
Project. I J Ment Health 1994;23:49–73.
31. Mrus JM,Williams PL, Tsevat J, et al. Gender differences in health-
related quality of life in patients with HIV/AIDS. Qual Life Res
2005;14:479–491.
32. Holbrook TL, Hoyt DB, Stein MB, et al. Gender differences in
long-term posttraumatic stress disorder outcomes after major
trauma: Women are at higher risk of adverse outcomes than men.
J Trauma 2002;53:882–888.
Pediatr Blood Cancer DOI 10.1002/pbc
714 Nathan et al.
33. Lindquist R, Dupuis G, Terrin ML, et al. Comparison of health-
related quality-of-life outcomes of men and women after
coronary artery bypass surgery through 1 year: Findings from the
POST CABG Biobehavioral Study. Am Heart J 2003;146:1038–
1044.
34. Langeveld NE, Grootenhuis MA, Voute PA, et al. Quality of life,
self-esteem and worries in young adult survivors of childhood
cancer. Psycho Oncol 2004;13:867–881.
35. Castleberry RP. Neuroblastoma. Eur J Cancer 1997;33:1430–
1437.
36. Ritchey ML, Green DM, Thomas PR, et al. Renal failure in Wilms
tumor patients: A report from the National Wilms Tumor Study
Group. Med Pediatr Oncol 1996;26:75–80.
37. Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure
after treatment forWilms tumor: A report from the NationalWilms
Tumor Study group. J Clin Oncol 2001;19:1926–1934.
38. Kalapurakal JA, Peterson S, Peabody EM, et al. Pregnancy
outcomes after abdominal irradiation that included or excluded
the pelvis in childhood Wilms tumor survivors: A report from the
National Wilms Tumor Study. Int J Radiat Oncol Biol Phys 2004;
58:1364–1368.
39. Paulino AC, Fowler BZ. Risk factors for scoliosis in children with
neuroblastoma. Int J Radiat Oncol Biol Phys 2005;61:865–869.
40. HooverM,BowmanLC,Crawford SE, et al. Long-termoutcome of
patients with intraspinal neuroblastoma. Med Pediatr Oncol
1999;32:353–359.
Pediatr Blood Cancer DOI 10.1002/pbc
HRQL After Wilms Tumor or Neuroblastoma 715
